Since PD-1 blockade has been approved by the FDA to treat metastatic melanoma, non-small cell lung cancer and kidney cancers, our study provides a novel approach to improve the efficacy of PD-1 or B7-H1 blockade therapy by including CpG. The gene discussed is CD274; the disease is metastatic melanoma.